135 related articles for article (PubMed ID: 34907994)
21. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Nuclear Grade, Necrosis, and Histologic Subtype Between Biopsy and Resection in Pleural Malignant Mesothelioma: An International Multi-Institutional Analysis.
Schulte JJ; Chapel DB; Attanoos R; Brcic L; Burn J; Butnor KJ; Chang N; Chen H; Dacic S; De Perrot M; Fukuoka J; Galateau-Salle F; Godschachner T; Hiroshima K; Klebe S; Krausz T; Litzky L; Marchevsky AM; Mueller J; Nabeshima K; Nicholson AG; Pal P; Roden AC; Rorvig S; Santoni-Rugiu E; Tazelaar H; Tsao MS; Walts AE; Weynand B; Zaizen Y; Zhang YZ; Husain AN
Am J Clin Pathol; 2021 Nov; 156(6):989-999. PubMed ID: 33978147
[TBL] [Abstract][Full Text] [Related]
23. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
[TBL] [Abstract][Full Text] [Related]
24. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
Sauter JL; Dacic S; Galateau-Salle F; Attanoos RL; Butnor KJ; Churg A; Husain AN; Kadota K; Khoor A; Nicholson AG; Roggli V; Schmitt F; Tsao MS; Travis WD
J Thorac Oncol; 2022 May; 17(5):608-622. PubMed ID: 35026477
[TBL] [Abstract][Full Text] [Related]
25. Multicenter study of diffuse pleural mesothelioma. Histopathological and immunohistochemical features.
Poleri C; Acosta Haab G; Falcoff N; Guman G; Dalurzo L; Iotti A; Martín ME; Olmedo G; Rayá M; Reginatto A; Werbach A; Demelli G; Labanca MJ; Leguina L; Mora MF
Medicina (B Aires); 2022; 82(2):210-216. PubMed ID: 35417384
[TBL] [Abstract][Full Text] [Related]
26. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
[TBL] [Abstract][Full Text] [Related]
27. Histopathological features of epithelioid malignant pleural mesotheliomas in patients with extended survival.
Paajanen J; Laaksonen S; Kettunen E; Ilonen I; Vehmas T; Salo J; Räsänen J; Sutinen E; Ollila H; Mäyränpää MI; Myllärniemi M; Wolff H
Hum Pathol; 2020 Apr; 98():110-119. PubMed ID: 32142836
[TBL] [Abstract][Full Text] [Related]
28. Histopathological typing in diffuse malignant epithelioid mesothelioma: implication for prognosis and molecular basis.
Forest F; Laville D; Habougit C; Corbasson M; Bayle-Bleuez S; Tissot C; Fournel P; Tiffet O; Péoc'h M
Pathology; 2021 Oct; 53(6):728-734. PubMed ID: 33965253
[TBL] [Abstract][Full Text] [Related]
29. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.
Kadota K; Suzuki K; Sima CS; Rusch VW; Adusumilli PS; Travis WD
J Thorac Oncol; 2011 May; 6(5):896-904. PubMed ID: 21358344
[TBL] [Abstract][Full Text] [Related]
30. The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.
Chou A; Toon CW; Clarkson A; Sheen A; Sioson L; Gill AJ
Histopathology; 2018 Feb; 72(3):509-515. PubMed ID: 28889523
[TBL] [Abstract][Full Text] [Related]
31. BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
Louw A; Panou V; Szejniuk WM; Meristoudis C; Chai SM; van Vliet C; Lee YCG; Dick IM; Firth T; Lynggaard LA; Asghari AB; Vyberg M; Hansen J; Creaney J; Røe OD
J Thorac Oncol; 2022 Jul; 17(7):921-930. PubMed ID: 35489694
[TBL] [Abstract][Full Text] [Related]
32. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
33. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients.
Liu S; Staats P; Lee M; Alexander HR; Burke AP
Pathology; 2014 Dec; 46(7):604-9. PubMed ID: 25393250
[TBL] [Abstract][Full Text] [Related]
34. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
35. What's new in mesothelioma.
Ascoli V; Murer B; Nottegar A; Luchini C; Carella R; Calabrese F; Lunardi F; Cozzi I; Righi L
Pathologica; 2018 Mar; 110(1):12-28. PubMed ID: 30259910
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.
Chirieac LR; Hung YP; Foo WC; Hofer MD; VanderLaan PA; Richards WG; Sugarbaker DJ; Bueno R
Cancer; 2019 Dec; 125(23):4164-4171. PubMed ID: 31390057
[TBL] [Abstract][Full Text] [Related]
37. BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report.
Rossi G; Righi L; Barbisan F; Tiseo M; Spagnolo P; Grosso F; Pisapia P; Malapelle U; Sculco M; Dianzani I; Abate-Daga L; Davolio MC; Ceresoli GL; Galetta D; Pasello G; Novello S; Bironzo P
J Pers Med; 2024 Apr; 14(4):. PubMed ID: 38673021
[TBL] [Abstract][Full Text] [Related]
38. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
Lim JH; Choi JY; Im Y; Yoo H; Jhun BW; Jeong BH; Park HY; Lee K; Kim H; Kwon OJ; Han J; Ahn MJ; Kim J; Um SW
PLoS One; 2020; 15(2):e0229299. PubMed ID: 32069313
[TBL] [Abstract][Full Text] [Related]
40. Association Between Clinicopathological Factors and Genomic Abnormalities Detected by FISH Analysis in Epithelioid Diffuse Malignant Pleural Mesothelioma.
Takeda M; Kasai T; Hatakeyama K; Nakai T; Itami H; Uchiyama T; IIzuka N; Maruyama H; Ohbayashi C
Int J Surg Pathol; 2017 Dec; 25(8):668-673. PubMed ID: 28673192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]